Oramed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Aug '21 Aug 31, 2021
Revenue	2	-	1.34	2.7	2.71	2.7
Revenue Growth (YoY)	-	-	-50.42%	-0.33%	0.33%	-0.33%
Cost of Revenue	1.99	-	-	-	-	-
Gross Profit	0.01	-	1.34	2.7	2.71	2.7
Selling, General & Admin	7.17	6.46	8.14	15.66	12.58	5.94
Research & Development	5.85	6.32	8.97	27.64	27.11	20.99
Operating Expenses	13.02	12.78	17.11	43.3	39.69	26.93
Operating Income	-13.01	-12.78	-15.77	-40.6	-36.98	-24.22
Interest Expense	-	-0.85	-2.04	-	-	-
Interest & Investment Income	3.36	5	8.17	3.57	0.47	0.35
Currency Exchange Gain (Loss)	0.17	0.17	-0.12	0.18	-0.03	-0
Other Non Operating Income (Expenses)	0.62	-0.04	-1.54	-0.01	-0.01	-0.01
EBT Excluding Unusual Items	-8.86	-8.5	-11.3	-36.86	-36.55	-23.88
Gain (Loss) on Sale of Investments	64.6	-7.42	16.39	-0.81	-0.22	0.9
Pretax Income	55.74	-15.92	5.09	-37.66	-36.77	-22.99
Income Tax Expense	11.94	3.18	-	0.1	-	-
Earnings From Continuing Operations	43.81	-19.1	5.09	-37.76	-36.77	-22.99
Minority Interest in Earnings	0.04	0.04	0.44	1.2	1.76	0.75
Net Income	43.85	-19.06	5.53	-36.56	-35	-22.24
Net Income to Common	43.85	-19.06	5.53	-36.56	-35	-22.24
Shares Outstanding (Basic)	41	41	40	39	37	28
Shares Outstanding (Diluted)	42	41	41	39	37	28
Shares Change (YoY)	3.29%	0.65%	4.02%	5.08%	30.36%	16.71%
EPS (Basic)	1.06	-0.47	0.14	-0.94	-0.94	-0.78
EPS (Diluted)	1.03	-0.48	0.14	-0.94	-0.94	-0.78
Free Cash Flow	-10.61	-8.43	-10.55	-28.41	-33.39	-21.56
Free Cash Flow Per Share	-0.25	-0.21	-0.26	-0.73	-0.90	-0.76
Gross Margin	0.65%	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-650.55%	-	-1176.79%	-1501.96%	-1363.50%	-896.15%
Profit Margin	2192.60%	-	412.31%	-1352.61%	-1290.71%	-822.72%
Free Cash Flow Margin	-530.40%	-	-787.24%	-1051.20%	-1231.31%	-797.48%
EBITDA	-12.89	-12.59	-15.57	-40.54	-36.92	-24.15
D&A For EBITDA	0.12	0.19	0.2	0.06	0.05	0.08
EBIT	-13.01	-12.78	-15.77	-40.6	-36.98	-24.22

Source: S&P Global Market Intelligence. Standard template. Financial Sources.